Mismatch Repair Pathway, MLH1, MSH2 and Mutations in Prostate Cancer.

Authors

Himanshu, Md Ali Osama, Lavleen Singh, Riyaz Ahmad Mir, Atul Batra, Ranjit K Sahoo, Brusabhanu Nayak, Amlesh Seth, Venkateswaran K Iyer

Published in

International journal of surgical pathology. Pages 10668969261483643. Oct 09, 2026. Epub Oct 09, 2026.

Abstract

ObjectivesThe DNA mismatch repair (MMR) pathway preserves genomic stability by correcting replication errors, with MLH1 and MSH2 playing central roles in mismatch recognition and repair. Loss of these proteins results in microsatellite instability, increased mutational burden, and genomic instability, contributing to prostate cancer development and progression. Emerging evidence suggests that MMR alterations define a distinct and clinically relevant subset of prostate cancer.MethodsA narrative literature review was performed using PubMed, Scopus, and Google Scholar databases. Articles published in English up to January 2026 were screened using combinations of the keywords "prostate cancer," "mismatch repair," "MLH1," "MSH2," "microsatellite instability," and "DNA repair." Original studies, clinical trials, genomic analyses and relevant review articles focusing on MMR alterations in prostate cancer were included.ResultsGermline MMR mutations are uncommon in prostate cancer; however, somatic alterations, particularly involving MSH2 and less frequently MLH1, are enriched in advanced and metastatic disease. MMR-deficient tumors demonstrate high tumor mutational burden, increased neoantigen formation, enhanced immune infiltration, and upregulation of immune checkpoint molecules such as PD-L1, contributing to responsiveness to immunotherapy.ConclusionMLH1 and MSH2 alterations define a clinically significant molecular subtype of prostate cancer. Identification of MMR deficiency can guide immunotherapy selection, supporting the integration of molecular profiling into routine clinical practice.

PMID:
42852818
Bibliographic data and abstract were imported from PubMed on 09 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.